Alkermes Earnings Call: LUMRYZ Momentum Drives Growth

Alkermes plc ((ALKS)) has held its Q1 earnings call. Read on for the main highlights of the call.

Alkermes’ latest earnings call struck an upbeat tone as management highlighted powerful revenue growth, a standout launch for newly acquired LUMRYZ, and a sizable beat on adjusted EBITDA. Executives acknowledged GAAP losses, higher leverage and near‑term margin pressure, but framed these as the cost of scaling a broader sleep and neuroscience platform that they say is already showing commercial traction.

Proprietary Portfolio Fuels Strong Topline Growth

Net sales from Alkermes’ proprietary products jumped 38% year over year to $338.1 million in the first quarter, driving total revenue to $392.9 million. Management emphasized that this step‑up confirms the durability of the company’s core franchises while providing the funding base for its expanding pipeline and integration of Avadel.

Key Brands Deliver Solid, Visible Growth

Flagship addiction therapy VIVITROL generated $112.4 million in Q1 sales, sitting comfortably on the path toward its full‑year guidance of $460 million to $480 million. ARISTADA posted $93.8 million with 2026 guidance of $365 million to $385 million, while antipsychotic LYBALVI booked $92.4 million, up 32% year over year with 21% TRx growth and projected 2026 sales of $380 million to $400 million.

Avadel Integration and LUMRYZ Launch Build Momentum

Alkermes closed its acquisition of Avadel in mid‑February and wasted little time demonstrating revenue synergies from LUMRYZ. The once‑nightly oxybate therapy delivered about $39.5 million of net sales in the six weeks following close and roughly $72 million for the full quarter, ending Q1 with about 3,600 patients on therapy and projected 2026 net sales of $350 million to $370 million.

Adjusted EBITDA Beat Strengthens Profitability Narrative

The company posted adjusted EBITDA of $80.3 million, far ahead of prior Q1 guidance of $30 million to $50 million and setting the stage for stronger near‑term profitability. Management now expects second‑quarter adjusted EBITDA of $100 million to $120 million and full‑year positive EBITDA in the $105 million to $135 million range, highlighting operational leverage despite elevated investment.

Accounting Refinements Ease Cost Outlook

Revised purchase price accounting for the Avadel deal significantly reduced expected inventory step‑up and amortization charges. LUMRYZ inventory step‑up is now forecast at about $105 million this year versus a previous estimate around $150 million, bringing expected 2026 cost of goods sold down to $320 million to $340 million and trimming annual intangible amortization to $75 million to $85 million.

Orexin Pipeline Advances on Multiple Fronts

Alkermes highlighted substantial progress in its orexin portfolio anchored by alixorexton, with the Phase III Brilliance program now open for enrollment in both narcolepsy type 1 and type 2. Additional readouts include Vibrance‑2 NT2 data slated for June and a Phase II Vibrance‑3 study in idiopathic hypersomnia on track to complete in the fourth quarter, supplemented by new molecules ALKS 7290 and ALKS 4510 moving through early‑stage trials.

Balance Sheet Re‑Tooled and Capital Returned to Shareholders

To fund the Avadel acquisition, the company deployed roughly $775 million of cash and added $1.525 billion of term loans maturing in 2031, ending the quarter with about $538 million in cash and investments. Despite this higher leverage, Alkermes still repurchased about 1 million shares for $28 million, leaving $172 million remaining under its authorization to support shareholder returns.

GAAP Loss and Negative GAAP EBITDA Reflect Investment Phase

The quarter’s headline GAAP metrics underscored the cost of the company’s aggressive expansion, with a net loss of $66.5 million and GAAP EBITDA of negative $30.1 million. Management tied these figures to acquisition‑related charges and elevated operating expenses, arguing that the underlying adjusted results better capture the health of the business as integration progresses.

R&D Spend Climbs as Pipeline Activity Ramps

Research and development expenses rose to $103.3 million from $71.8 million a year earlier, an increase of roughly $31.5 million tied primarily to the start of alixorexton Phase III and other orexin programs. The company guided to further R&D growth in the second quarter, targeting $110 million to $120 million as it leans into late‑stage trials and new indications.

SG&A Inflation Driven by Deal Costs and Integration

Selling, general and administrative expense hit $264.6 million in Q1, though this total included around $55 million of one‑time costs associated with closing the Avadel transaction. On an adjusted basis, SG&A of $209.4 million still represented a notable increase from $171.7 million last year, signaling a higher ongoing cost base post‑integration to support LUMRYZ and the broader portfolio.

Inventory Step‑Up and COGS Pressure Margins Near Term

Cost of goods sold reached $61.6 million in the quarter, inflated by LUMRYZ inventory step‑up, and management said COGS would have been $48.9 million excluding that accounting impact. With a full quarter of LUMRYZ recognized in the second quarter, COGS are forecast to climb to $85 million to $95 million, temporarily compressing margins as step‑up amortization runs through the P&L.

Higher Leverage and Reduced Cash Cushion Raise Risk Profile

The debt taken on to fund Avadel has meaningfully increased Alkermes’ leverage and reduced its cash buffer, a point management acknowledged as a key financial trade‑off. Executives stressed their intention to use future cash flows to pay down the term loans over time, but investors will need to watch execution closely given the more levered balance sheet.

Gross‑to‑Net and Market Dynamics Create Revenue Headwinds

LYBALVI’s gross‑to‑net adjustments were about 33% in the first quarter and are expected to widen into the mid‑30% range this year, which will weigh on realized pricing and margins even as prescription volume grows. The company also noted that external competitive forces, including Eli Lilly’s move into orexin and potential generic competition for Xyrem around 2027, add uncertainty to the long‑term oxybate landscape.

Tax Outlook Softens Earnings Trajectory

Alkermes now expects neither income tax expense nor benefit for the full year, a change from the previously anticipated roughly $20 million tax benefit that would have supported net income. While not a major swing factor compared with operating drivers, the revised tax view removes a modest tailwind from the bottom‑line outlook and reinforces the importance of execution on EBITDA growth.

Guidance Points to Strong Revenue and EBITDA Despite GAAP Loss

Management raised the bar for 2026, projecting full‑year revenue above $1.7 billion with adjusted EBITDA greater than $370 million, even as GAAP net income remains negative at an expected loss of $70 million to $90 million and GAAP EBITDA of $105 million to $135 million. Product‑level forecasts call for steady growth across VIVITROL, ARISTADA and LYBALVI, plus LUMRYZ sales of $350 million to $370 million, while second‑quarter guidance features proprietary net sales of $385 million to $405 million and adjusted EBITDA of $100 million to $120 million.

Alkermes’ earnings call painted the picture of a company trading near‑term GAAP profitability and balance‑sheet conservatism for faster growth in high‑value sleep and psychiatry markets. With LUMRYZ ramping, core brands performing and the orexin pipeline progressing, investors are being asked to tolerate elevated spending and leverage in exchange for what management believes is a significantly larger long‑term earnings base.